Last 46 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Xtant Medical Holdings, Inc.'s quarterly P/E stands at 18.4x.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.75 | 18.43 | 7.73 | 293.75 | — | — | — | — | — | 4.04 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.68 | 0.72 | 0.78 | 0.51 | 0.49 | 0.82 | 0.69 | 1.37 | 1.31 | 1.49 | 1.25 | 0.97 | 1.17 |
| — | -11.3% | +13.1% | -62.5% | -62.6% | -45.2% | -45.2% | +41.3% | +11.6% | +28.5% | +68.6% | -15.4% | +34.2% | |
| P/B Ratio | 1.77 | 1.91 | 2.26 | 1.54 | 1.43 | 2.00 | 1.82 | 3.19 | 2.86 | 2.73 | 3.27 | 2.12 | 2.09 |
| — | -4.2% | +24.1% | -51.9% | -49.9% | -26.8% | -44.2% | +50.5% | +36.7% | +33.2% | +102.9% | +4.8% | +32.6% | |
| P/FCF | — | 5.76 | 30.16 | 193.58 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 8.00 | 6.04 | 11.30 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 12.00 | 7.28 | 22.41 | — | — | — | — | — | 5.32 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Xtant Medical Holdings, Inc.'s operating margin was 7.6% in Q3 2025, down 5.4 pp QoQ and up 21.2 pp YoY. The trailing four-quarter average of 4.5% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 13.3% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 58.2% | 66.1% | 68.6% | 61.5% | 50.8% | 58.4% | 62.1% | 62.1% | 61.0% | 61.3% | 61.6% | 58.7% | 54.4% |
| — | +13.3% | +10.5% | -0.9% | -16.6% | -4.8% | +0.8% | +5.7% | +12.1% | +12.3% | +12.3% | +0.7% | -1.2% | |
| Operating Margin | -10.3% | 7.6% | 13.1% | 3.2% | -6.0% | -13.5% | -9.8% | -12.4% | -13.5% | -13.5% | -6.9% | -8.8% | -11.3% |
| — | +156.5% | +232.7% | +126.0% | +55.9% | +0.1% | -43.1% | -41.7% | -19.9% | -3.0% | +19.2% | +37.8% | +17.5% | |
| Net Margin | -14.0% | 3.9% | 10.0% | 0.2% | -10.0% | -18.0% | -12.9% | -15.8% | -15.3% | 36.9% | -10.8% | -11.6% | -14.5% |
| — | +121.9% | +177.7% | +101.1% | +34.4% | -148.7% | -19.1% | -36.3% | -5.8% | +326.8% | +3.3% | +32.2% | +11.5% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -34.9% | 2.6% | 7.7% | 0.1% | -7.1% | -11.1% | -8.3% | -8.9% | -8.1% | 21.6% | -6.9% | -6.2% | -6.6% |
| — | +123.9% | +192.2% | +101.5% | +12.1% | -151.4% | -21.1% | -43.0% | -23.0% | +379.1% | -15.5% | +15.5% | +8.2% | |
| ROA | -17.6% | 1.2% | 3.6% | 0.1% | -3.3% | -5.2% | -4.1% | -4.7% | -4.7% | 11.7% | -3.4% | -3.4% | -3.8% |
| — | +124.1% | +187.4% | +101.3% | +29.5% | -144.0% | -19.6% | -40.2% | -22.7% | +371.4% | -5.5% | +18.0% | +8.1% | |
| ROIC | -12.8% | 2.5% | 4.6% | 1.1% | -1.9% | -3.8% | -3.0% | -3.7% | -4.1% | -4.3% | -2.1% | -3.0% | -4.2% |
| — | +166.6% | +251.5% | +129.8% | +53.5% | +11.0% | -43.8% | -25.0% | +2.0% | +11.1% | +36.7% | +36.4% | +10.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Xtant Medical Holdings, Inc.'s Debt/EBITDA ratio is 8.8x, up from 6.4x last quarter — elevated, raising questions about debt serviceability. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.82 | 0.64 | 0.76 | 0.78 | 0.82 | 0.79 | 0.78 | 0.60 | 0.46 | 0.42 | 0.76 | 0.66 | 0.50 |
| — | -18.0% | -1.7% | +29.6% | +78.3% | +86.7% | +2.2% | -8.6% | -8.2% | -7.9% | +22.2% | +11.9% | -8.4% | |
| Debt / EBITDA | — | 8.78 | 6.40 | 16.05 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.35 | 2.21 | 2.47 | 2.34 | 2.35 | 2.12 | 2.44 | 2.34 | 2.82 | 2.92 | 2.33 | 2.12 | 3.24 |
| — | +4.0% | +1.4% | -0.1% | -16.8% | -27.5% | +4.6% | +10.5% | -12.9% | -26.4% | -34.8% | -44.4% | -19.0% | |
| Quick Ratio | 1.00 | 1.06 | 1.16 | 1.03 | 1.00 | 0.88 | 1.01 | 0.98 | 1.22 | 1.36 | 1.13 | 1.05 | 2.10 |
| — | +20.8% | +15.2% | +4.8% | -18.1% | -35.4% | -11.1% | -6.5% | -42.2% | -45.1% | -48.2% | -53.9% | -11.6% | |
| Interest Coverage | -2.90 | 2.81 | 4.61 | 1.02 | -1.66 | -3.15 | -2.97 | -4.16 | -4.65 | -4.45 | -1.77 | -2.74 | -3.48 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying XTNT stock.
Xtant Medical Holdings, Inc.'s current P/E is -4.8x. The average P/E over the last 3 quarters is 106.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Xtant Medical Holdings, Inc.'s current operating margin is -10.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Xtant Medical Holdings, Inc.'s business trajectory between earnings reports.